Epilepsy

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the necessary steps in validating and utilizing heart rate variability as a biomarker for SUDEP. [WATCH TIME: 3 minutes]

Reduced low-frequency power measured at rest was independently associated with an elevated SUDEP risk, presumably through arrhythmogenic mechanisms.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending November 20, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the FDA approval of cannabidiol as an oral solution for the treatment of seizures, specifically for both Dravet and Lennox-Gastaut syndromes.

Two experts detail the current treatment options for Dravet and Lennox-Gastaut syndromes and how they select which patients should use a specific drug.

The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]

In addition to changes in CCL2 levels, anxiety and health-related quality of life were both significantly increased in both the valproate and add-on levetiracetam groups.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed his recently published research, which identified a novel biomarker for sudden unexpected death in epilepsy.

Beginning enrollment in 2022, the NAUTILUS pivotal study will be the first in the United States to evaluate brain-responsive neuromodulation in patients with idiopathic generalized epilepsy.

Drs Thiele and Wirrell explain how clinicians diagnose patients with Dravet or Lennox-Gastaut syndromes and the typical triggers patients will exhibit.

Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, discuss the commonality of childhood epilepsies, as well as the differences between Dravet syndrome and Lennox-Gastaut syndrome.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the critical findings on how heart rate variability may stratify individual SUDEP risk. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive.

A stronger association between the 2 conditions was seen in younger patients and men with epilepsy than their counterparts in the matched cohort of more than 9000 individuals.

Having previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.

Originally approved in 1996, the therapy, indicated for the treatment of to partial-onset and tonic clonic seizures, is now available in a liquid formulation.

NRTX-1001 will be first evaluated in an open-label dose-escalation study, followed by a randomized blinded portion, with both featuring patients with drug-resistant mesial temporal epilepsy.

A total of 12 studies evaluating children and adolescents with nonepileptic seizures were included, with both top-down and bottom-up approaches employed.

Here's what is coming soon to NeurologyLive.

A total of 14 children and their mothers were evaluated in the study, and although improvements in sleep scores were also reported, they were not statistically significant.

Included participants were enrolled in Medicaid, which includes some of the most vulnerable patients in this population, investigators said.

Neurology News Network for the week ending November 6, 2021.